BioCentury
ARTICLE | Clinical News

Disarm validates biomarkers for SARM1 inhibition

November 30, 2018 6:26 PM UTC

Disarm Therapeutics Inc. (Cambridge, Mass.), which is developing small molecule inhibitors of sterile α and TIR motif containing 1 (SARM1) to prevent axonal degeneration in a range of neurological disorders, said it validated two biomarkers that measure SARM1 activity and axonal degeneration.

In a poster presented at the Neuroscience meeting in San Diego, Disarm showed that deletion of SARM1 protected axons in the central and peripheral nervous systems with corresponding reductions in blood levels of neurofilament light (NEFL; NF-L) and cyclic ADP-ribose (cADPR)...